FNCRX
Price
$44.86
Change
+$0.79 (+1.79%)
Updated
Jun 2 closing price
Net Assets
532.53M
TRNEX
Price
$49.92
Change
+$0.91 (+1.86%)
Updated
Jun 2 closing price
Net Assets
3.14B
Interact to see
Advertisement

FNCRX vs TRNEX

Header iconFNCRX vs TRNEX Comparison
Open Charts FNCRX vs TRNEXBanner chart's image
FNCRX vs TRNEX Comparison Chart in %
View a ticker or compare two or three
VS
FNCRX vs. TRNEX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FNCRX is a Hold and TRNEX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
TRNEX has more cash in the bank: 3.14B vs. FNCRX (533M). TRNEX pays higher dividends than FNCRX: TRNEX (2.28) vs FNCRX (0.86). FNCRX was incepted earlier than TRNEX: FNCRX (21 years) vs TRNEX (10 years). FNCRX (1.76) is less costly to investors than TRNEX (0.57). TRNEX is a more actively managed with annual turnover of: 38.60 vs. FNCRX (19.72). FNCRX has a lower initial minimum investment than TRNEX: FNCRX (1000) vs TRNEX (500000). FNCRX annual gain was more profitable for investors over the last year : 54.55 vs. TRNEX (31.73). FNCRX return over 5 years is better than : 110.95 vs. TRNEX (44.77).
FNCRXTRNEXFNCRX / TRNEX
Total Expense Ratio1.750.57307%
Annual Report Gross Expense Ratio1.760.57309%
Fund Existence21 years10 years-
Gain YTD23.44521.132111%
Front LoadN/AN/A-
Min. Initial Investment10005000000%
Min. Initial Investment IRAN/AN/A-
Net Assets533M3.14B17%
Annual Yield % from dividends0.862.2838%
Returns for 1 year54.5531.73172%
Returns for 3 years72.9834.09214%
Returns for 5 years110.9544.77248%
Returns for 10 years98.8589.58110%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REAL9.790.09
+0.93%
RealReal (The)
NGG80.640.64
+0.80%
National Grid PLC
FOSL4.13N/A
N/A
Fossil Group
GTLB31.82-1.97
-5.83%
GitLab
KTTA0.64-0.07
-9.79%
Pasithea Therapeutics Corp